MedTrace Logo

Study of Blood and Tissue Samples From Patients With Locally Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Treated With Bevacizumab, Carboplatin, and Paclitaxel

NCT00900172 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2017-05-19

No results posted yet for this study

Summary

RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This research study is looking at blood and tissue samples from patients with locally advanced, metastatic, or recurrent non-small cell lung cancer treated with bevacizumab, carboplatin, and paclitaxel.

Conditions

Interventions

BIOLOGICAL

bevacizumab

DRUG

carboplatin

DRUG

paclitaxel

GENETIC

gene expression analysis

GENETIC

polymerase chain reaction

GENETIC

polymorphism analysis

OTHER

laboratory biomarker analysis

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • ECOG-ACRIN Cancer Research Group

    lead NETWORK

Principal Investigators

  • Heinz-Josef Lenz, MD · University of Southern California

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-15
Primary Completion
2009-04-15
Completion
2009-04-15

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00900172 on ClinicalTrials.gov